fda warning letters glp-1 september 2025 issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's crackdown on misleading CDER Warning Letters Jump 50%
Description
Nature 494 , 256260 (2013)

For injectable access without insurance, Direct Meds has a meaningful price advantage when total program cost - not just medication price - is compared
doi: 10.1210/en.2011-1070

Pharmacol Res (2020) 152:104615

It is how the drug is made, who is allowed to make it, and what regulatory oversight applies